Stapokibart
Based on 1 Customer Validation
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.37%
- CAS No.: 2734715-10-5
- Masse moléculaire:144.3 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG4 kappa
Human
|
STAT6 |
IL-13 |
IL-4 |
Stapokibart binds to IL-4Rα from human, cynomolgus monkey, and rat with KD values of 0.25 nM, 1.50 nM, and 2.75 nM, respectively[2].
Stapokibart blocks the interaction of IL-4 with IL-4Rα with an IC50 of 0.40 nM[2].
Stapokibart inhibits IL-4-induced STAT6 activation with an IC50 of 0.039 nM and IL-13-induced STAT6 activation with an IC50 of 0.041 nM[2].
Stapokibart inhibits IL-4-induced TF-1 cell proliferation with an IC50 of 1.75 nM and IL-13-induced proliferation with an IC50 of 0.13 nM[2].
Stapokibart suppresses IL-4-induced CD23 upregulation on Ramos cells with an IC50 of 0.53 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Stapokibart (25-100 mg/kg; s.c.) improves Ovalbumin-induced rhinitis and AD-like dermatitis in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) rats (male, 6-8 weeks old) + OVA-induced rhinitis model[2]
-
Dosage:25 mg/kg, 50 mg/kg, 100 mg/kg
-
Administration:Subcutaneous injection; on days 0, 3, 5, 7, 10, 14, 17, 21, 23, 25, and 27
-
Result:Reduced rubbing frequency and sneezing counts on days 23, 25, and 27 (dose-dependent).
Decreased eosinophils and macrophages in nasal mucosa.
Lowered eotaxin levels in NALF and serum total IgE/OVA-specific IgE,
Reduced mRNA levels of IL-4, IL-13, IL-5, and MUC5AC in nasal tissues.
Alleviated nasal mucosa eosinophil infiltration, goblet cell metaplasia, and mast cell degranulation.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Daudi cells labelling IL-4Ra (red) with Stapokibart (anti-IL-4Ra) (HY-P990093). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99993, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2734715-10-5
-
Appearance Liquid
-
Masse moléculaire 144.3 kDa
-
Color Colorless to light yellow
-
SMILES
[Stapokibart]
-
Synonyms
CM310
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Yuan Zhang, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul 5:61:102076. [Content Brief]
[2]. Liu W, et al. Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation. iScience. 2024 Aug 13;27(9):110721. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Stapokibart Related Classifications
HY-P990093 Related Classifications
Powered by Bioz